1. Home
  2. CODA vs IMUX Comparison

CODA vs IMUX Comparison

Compare CODA & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

HOLD

Current Price

$11.66

Market Cap

134.4M

Sector

Industrials

ML Signal

HOLD

Logo Immunic Inc.

IMUX

Immunic Inc.

HOLD

Current Price

$12.99

Market Cap

152.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CODA
IMUX
Founded
1994
2016
Country
United States
United States
Employees
N/A
66
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
134.4M
152.6M
IPO Year
2007
2013

Fundamental Metrics

Financial Performance
Metric
CODA
IMUX
Price
$11.66
$12.99
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$36.00
AVG Volume (30 Days)
126.8K
1.8M
Earning Date
06-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
15.62
38.00
EPS
0.08
N/A
Revenue
$20,316,161.00
N/A
Revenue This Year
$18.28
N/A
Revenue Next Year
$12.62
N/A
P/E Ratio
$148.19
N/A
Revenue Growth
4.98
N/A
52 Week Low
$5.98
$0.51
52 Week High
$18.00
$12.25

Technical Indicators

Market Signals
Indicator
CODA
IMUX
Relative Strength Index (RSI) 46.25 86.59
Support Level $10.81 $0.75
Resistance Level $12.22 N/A
Average True Range (ATR) 0.51 1.03
MACD 0.05 0.36
Stochastic Oscillator 51.68 97.66

Price Performance

Historical Comparison
CODA
IMUX

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

About IMUX Immunic Inc.

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. It operates in one segment which is Life science segment.

Share on Social Networks: